Relative Bioavailability Of Two Formulations Of Moroctocog Alfa (AF-CC)
Status:
Completed
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
This study is being conducted to compare how moroctocog alfa (AF-CC) acts in the body when
administered as 2 different dose presentations. The first is the current product vials with
prefilled diluent syringes and the second is a new dual-chamber syringe dose presentation.